The shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) has been pegged with a rating of Overweight by JP Morgan in its latest research note that was published on June 15th, 2018. The research company has also assigned a $11 price target. JP Morgan wasn’t the only research firm that published a report of TherapeuticsMD, Inc., with other equities research analysts also giving their opinion on the stock. Morgan Stanley advised investors in its research note published on September 8th, 2017, to Equal-Weight the TXMD stock while also putting a $6 price target. The stock had earned Outperform rating from Oppenheimer when it published its report on July 11th, 2017. The stock was given Perform rating by Oppenheimer in its report released on May 9th, 2017. Jefferies was of a view that TXMD is Buy in its latest report on November 22nd, 2016 while giving it a price target of $18. Oppenheimer thinks that TXMD is worth Outperform rating. This was contained in the firm’s report on November 22nd, 2016.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $16.00. The price of the stock the last time has raised by 49.22% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 53.28.
The shares of the company dipped by -3.68% during the trading session on Friday, reaching a low of $5.18 while ending the day at $5.23. During the trading session, a total of 2.96 million shares were traded which represents a 4.83% incline from the average session volume which is 3.11M shares. TXMD had ended its last session trading at 5.43. TherapeuticsMD, Inc. currently has a market cap of $1.29B while its P/E earnings growth sits at 85.54, with a beta of 2.07. TherapeuticsMD, Inc. debt-to-equity ratio currently stands at 0.55, while its quick ratio hovers at 7.10. TXMD 52-week low price stands at $3.51 while its 52-week high price is $7.66.
The company in its last quarterly report recorded -$0.16 earnings per share which is above the -$0.21 predicted by most analysts. The TherapeuticsMD, Inc. generated $3.47 million in revenue during the last quarter, which is slightly lower than the $4.43 million predicted by analysts. In the second quarter last year, the firm recorded -$0.15 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 6.25%. TherapeuticsMD, Inc. has the potential to record -0.52 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Goldman published a research note on December 11th, 2018 where it informed investors and clients that Fidelity National Information Services, Inc. (NYSE:FIS) is now rated as Buy. Morgan Stanley also rated FIS as Initiated on September 8th, 2017, with its price target of suggesting that FIS could surge by 9.92% from its current share price. Even though the stock has been trading at $108.67/share, analysts expect it to surge higher by 0.30% to reach $121.00/share. It started the day trading at $109.22 and traded between $107.86 and $109.00 throughout the trading session.
A look at its technical shows that FIS’s 50-day SMA is 104.28 while its 200-day SMA stands at 105.32. The stock has a high of $110.83 for the year while the low is $92.12. The company’s P/E ratio currently sits at 48.36, while the P/B ratio is 3.55. The company’s average trading volume currently stands at 1.46M shares, which means that the short-interest ratio is just 2.26 days. Over the past seven days, the company moved, with its shift of 1.68%. Looking further, the stock has raised 4.14% over the past 90 days while it gained 2.96% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. T Rowe Price Associates Inc bought more FIS shares, increasing its portfolio by +3.06% during the last quarter. This move now sees T Rowe Price Associates Inc purchasing 932,733 shares in the last quarter, thus it now holds 31,391,517 shares of FIS, with a total valuation of $3,219,200,068. The Vanguard Group Inc meanwhile bought more FIS shares in the recently filed quarter, changing its stake to $2,492,979,937 worth of shares. Massachusetts Financial Services followed the path by decreasing its FIS portfolio by -0.80% in the quarter. This means that Massachusetts Financial Services sold -150,228 shares in the last quarter and now controls 18,714,919 shares of the FIS stock, with the valuation hitting $1,919,214,943.
Similarly, SSgA Funds Management Inc increased its Fidelity National Information Services, Inc. shares by +3.07% during the recently filed quarter. After buying 376,100 shares in the last quarter, the firm now controls 12,615,896 shares of Fidelity National Information Services, Inc. which are valued at $1,293,760,135. In the same vein, Longview Partners LLP decreased its Fidelity National Information Services, Inc. shares by during the most recent reported quarter. The firm sold -136,090 shares during the quarter which decreased its stakes to 9,926,665 shares and is now valued at $1,017,979,496. Following these latest developments, around 0.10% of Fidelity National Information Services, Inc. stocks are owned by institutional investors and hedge funds.